Dissertations / Theses on the topic 'Receptor do GHRH'

Tese(doutorado)-Universidade Federal do Rio Grande, Programa de Pós-Graduação em Aqüicultura, Instituto de Oceanografia, 2011.<br>Submitted by Cristiane Silva (cristiane_gomides@hotmail.com) on 2012-06-23T16:27:42Z No. of bitstreams: 1 tese corrigida marcio figueiredo.pdf: 4782449 bytes, checksum: df5bb424fe5c9736a80fdc4a63db03a1 (MD5)<br>Approved for entry into archive by Bruna Vieira(bruninha_vieira@ibest.com.br) on 2012-07-27T20:22:46Z (GMT) No. of bitstreams: 1 tese corrigida marcio figueiredo.pdf: 4782449 bytes, checksum: df5bb424fe5c9736a80fdc4a63db03a1 (MD5)<br>Made available in DSpace on 2012-07-27T20:22:46Z (GMT). No. of bitstreams: 1 tese corrigida marcio figueiredo.pdf: 4782449 bytes, checksum: df5bb424fe5c9736a80fdc4a63db03a1 (MD5) Previous issue date: 2011<br>A aquicultura tem crescido significativamente nas últimas décadas devido ao aumento da demanda de pescado no mundo e à estagnação do setor pesqueiro. Porém, este crescimento depende do desenvolvimento de novos pacotes tecnológicos que visem o aumento da produtividade. Uma alternativa é a manipulação genética (transgenia), sendo que o hormônio do crescimento (GH) tem sido o principal alvo das pesquisas com peixes transgênicos. Entretanto, está comprovado que o excesso de GH acarreta uma série de efeitos adversos devido a sua ação pleiotrópica. A ativação do eixo somatotrófico de forma tecido-específica e independente do excesso de hormônio circulante pode contornar estes problemas. Neste contexto, o objetivo desta tese foi superexpressar o gene do receptor do GH (GHR) no tecido muscular esquelético do zebrafish (Danio rerio) e estudar os efeitos desta manipulação sobre os mecanismos envolvidos na regulação gênica do crescimento muscular. A linhagem transgênica estável obtida expressa o GHR especificamente no tecido muscular 100 vezes mais do que os não transgênicos. Estes transgênicos não apresentaram aumento significativo no crescimento, provavelmente devido à queda na expressão do fator de crescimento tipo insulina I (IGF-I). Esta queda foi, provavelmente, relacionada à ação dos principais moduladores da sinalização do GH (SOCS1 e 3), os quais apresentaram-se aumentados nos transgênicos. Ainda, foi observada uma queda na expressão das principais proteínas musculares estruturais (Acta1, myhc4 e mylz2), o que explica a ausência de hipertrofia nos transgênicos. Por outro lado, o aumento na expressão dos principais fatores reguladores miogênicos (myod, myf5 e myog) explica a hiperplasia observada nas análises histológicas. Para verificar como a superexpressão do GHR ativou a transcrição dos fatores reguladores miogênicos (MRFs) e, por consequência a hiperplasia, foram estudados os possíveis mecanismos envolvidos neste processo. Dentre estes, tanto a via proliferativa (MEK/ERK) quanto à via relacionada com a síntese protéica (PI3K/Akt), não tiveram alteração na expressão de seus genes. Entretanto, foi observado aumento na expressão das proteínas de transporte para o núcleo (importinas 1, 3 e 1), podendo-se concluir que a ativação dos MRFs está relacionada ao transporte do GHR para o núcleo das células musculares. Desta forma, pode se concluir que hiperplasia e hipertrofia seguem duas vias de sinalização intracelular distintas, ambas desencadeadas pelo GH, mas reguladas por mecanismos diferentes.<br>Aquiculture practice has been significantly increasing during the last decades due to the fish rising demand and to fishery activity stagnation. However, such increase depends on new technological packages development aiming to productivity rises. Genetic manipulation is an alternative, once growth hormone (GH) has been the main target on transgenic fish researches. Nevertheless, it has been proved that GH excess leads to many adverse effects due to its pleiotropic action. The somatotropic axis activation in a tissue-specific manner and independent on the circulating hormone excess may bypass these problems. Following these ideas, the present thesis objective was overexpressing GH receptor’s gene (GHR), in zebrafish (Danio rerio) skeletal muscular tissue, and studying such manipulation effects over the mechanisms involved in muscular growth gene regulation. The stable transgenic lineage obtained expresses GHR, specifically in muscular tissue, 100 times more than non-transgenic. These transgenic did not present significant growth, possibly due to a gene expression fall in insulin-like growth factor I (IGF-I). The mentioned fall is, probably, related to GH main signaling modulators (SOCS1 and 3) action, which were increased in transgenic. Also, a gene expression fall from the main structural muscle proteins (Acta1, myhc4 and mylz2) was observed, explaining the transgenic hypertrophy absence. However, the main myogenic regulatory factors (myod, myf5 and myog) expression rising explains the observed hyperplasia in histological analysis. Intending to verify how GHR overexpression has activated the myogenic regulatory factors (MRFs) transcription and, consequently, the hyperplasia, the mechanisms possibly involved in this process were studied. Among these, even the proliferative pathway (MEK/ERK) or the pathway related to protein synthesis (PI3K/Akt), did not presented gene expression altering. However, a gene expression rise in transporting proteins into nucleus (importins 1, 3 and 1) was observed, which may be understood as a correlation between MRFs activation and GHR transport into muscular cell’s nucleus. Therefore, it may be understood that hyperplasia and hypertrophy follow two distinct intracellular signaling pathways, both triggered by GH, but regulated by different mechanisms. These data may be important for aquiculture new transgenic lineages development.

The last few years have seen dramatic advances in genomics, including the discovery of a large number of non-coding and antisense transcripts. This has revolutionised our understanding of multifaceted transcript structures found within gene loci and their roles in the regulation of development, neurogenesis and other complex processes. The recent and continuing surge of knowledge has prompted researchers to reassess and further dissect gene loci. The ghrelin gene (GHRL) gives rise to preproghrelin, which in turn produces ghrelin, a 28 amino acid peptide hormone that acts via the ghrelin receptor (growth hormone secretagogue receptor/GHSR 1a). Ghrelin has many important physiological and pathophysiological roles, including the stimulation of growth hormone (GH) release, appetite regulation, and cancer development. A truncated receptor splice variant, GHSR 1b, does not bind ghrelin, but dimerises with GHSR 1a, and may act as a dominant negative receptor. The gene products of ghrelin and its receptor are frequently overexpressed in human cancer While it is well known that the ghrelin axis (ghrelin and its receptor) plays a range of important functional roles, little is known about the molecular structure and regulation of the ghrelin gene (GHRL) and ghrelin receptor gene (GHSR). This thesis reports the re-annotation of the ghrelin gene, discovery of alternative 5’ exons and transcription start sites, as well as the description of a number of novel splice variants, including isoforms with a putative signal peptide. We also describe the discovery and characterisation of a ghrelin antisense gene (GHRLOS), and the discovery and expression of a ghrelin receptor (growth hormone secretagogue receptor/GHSR) antisense gene (GHSR-OS). We have identified numerous ghrelin-derived transcripts, including variants with extended 5' untranslated regions and putative secreted obestatin and C-ghrelin transcripts. These transcripts initiate from novel first exons, exon -1, exon 0 and a 5' extended 1, with multiple transcription start sites. We used comparative genomics to identify, and RT-PCR to experimentally verify, that the proximal exon 0 and 5' extended exon 1 are transcribed in the mouse ghrelin gene, which suggests the mouse and human proximal first exon architecture is conserved. We have identified numerous novel antisense transcripts in the ghrelin locus. A candidate non-coding endogenous natural antisense gene (GHRLOS) was cloned and demonstrates very low expression levels in the stomach and high levels in the thymus, testis and brain - all major tissues of non-coding RNA expression. Next, we examined if transcription occurs in the antisense orientation to the ghrelin receptor gene, GHSR. A novel gene (GHSR-OS) on the opposite strand of intron 1 of the GHSR gene was identified and characterised using strand-specific RT-PCR and rapid amplification of cDNA ends (RACE). GHSR-OS is differentially expressed and a candidate non-coding RNA gene. In summary, this study has characterised the ghrelin and ghrelin receptor loci and demonstrated natural antisense transcripts to ghrelin and its receptor. Our preliminary work shows that the ghrelin axis generates a broad and complex transcriptional repertoire. This study provides the basis for detailed functional studies of the the ghrelin and GHSR loci and future studies will be needed to further unravel the function, diagnostic and therapeutic potential of the ghrelin axis.

Made available in DSpace on 2014-08-20T13:32:53Z (GMT). No. of bitstreams: 1 dissertacao_augusto_schneider.pdf: 2025669 bytes, checksum: bde04bd1476df3f35564859c10477bca (MD5) Previous issue date: 2008-11-28<br>In non-ovarian tissues GHR expression is regulated by insulin concentrations and is correlated to IGF-I expression. In the ovary IGF-I expression is also related to insulin levels, however no correlation with GHR was demonstrated until now. The aim of this study was to investigate the effect of fasting or insulin administration on blood concentrations of glucose, nonsterified fatty acids, insulin, insulin like growth factor I (IGF-I) and estradiol and on follicular expression of growth hormone receptor (GHR) and IGF-I mRNA in ewes. Fifteen ewes received an intravaginal progesterone releasing device that was removed 6 days later (Day 0). In Day -2 the ewes were divided in: control group, which received maintenance diet, insulin group, which received insulin injections every 12 hours from Day -2 to 2 and fasting group, which was submitted to fasting from Day -2 to 2. The results of the current study revealed that insulin administration or fasting during the development of a follicular wave did not affect (P=0.22) follicular diameter, although insulin injection increased (P=0.02) estradiol production. There was no difference among groups for GHR or IGF-I mRNA expression in granulosa (P=0.62, 0.43) or theca cells (P=0.92, 0.43). For fasting group there was a positive correlation between glucose and estradiol (r=0.97, P=0.006) and granulosa cell IGF mRNA (r=0.96, P=0.03). For insulin group estradiol was positive correlated to follicular diameter (r=0.93, P=0.02) and granulosa cell GHR (r=0.87, P=0.05) and IGF-I mRNA (r=0.79, P=0.10). In conclusion, exogenous insulin or fasting did not affect follicular diameter and expression of GHR and IGF-I mRNA in the pre-ovulatory follicle, although exogenous insulin increased estradiol production.<br>Em tecidos não ovarianos a expressão do receptor do hormônio do crescimento (GHR) é regulada pelas concentrações de insulina e está correlacionada a expressão de fator de crescimento semelhante a insulina tipo I (IGF-I). No ovário a expressão de IGF-I também está relacionada aos níveis de insulina, porém ainda não foi demonstrada sua correlação com a expressão de GHR. O objetivo deste estudo foi investigar o efeito do jejum ou administração de insulina nos níveis de glucose, ácidos graxos não esterificados, uréia, IGF-I, insulina e estradiol e na expressão folicular de RNAm para GHR e IGF-I em ovelhas. Quinze ovelhas receberam um dispositivo intravaginal liberador de progesterona, que foi removido após seis dias (Dia 0). No Dia -2 as ovelhas foram dividas em: grupo controle, que recebeu uma dieta de manutenção; grupo insulina, que recebeu injeções de insulina a cada 12 horas do Dia -2 ao Dia 2 e grupo jejum, que foi submetido à dieta hídrica do Dia -2 ao Dia 2. Os resultados revelaram que a administração de insulina ou o jejum durante o desenvolvimento de uma onda folicular não influenciaram (P=0,22) o diâmetro folicular, no entanto a administração de insulina aumentou (P=0,02) a produção de estradiol. Não houve diferença entre os grupos para a expressão de RNAm para GHR e IGF-I nas células da granulosa(P=0,62; 0,43) ou teca (P=0,92; 0.43). Para o grupo jejum houve uma correlção positiva entre glucose e estradiol (r=0,97, P=0,006) e RNAm IGF-I nas células da granulosa (r=0,96, P=0,03). Para o grupo insulina o estradiol foi positivamente correlacionado ao diâmetro folicular (r=0,93, P=0,02) e expressão de RNAm para GHR (r=0,87, P=0,05) e IGF-I (r=0,79, P=0,10)nas células da granulosa. Em conclusão, a insulina exógena ou o jejum não afetaram o diâmetro folicular e a expressão de mRNA para GHR e IGF-I no folículo pré-ovulatório, apesar da insulina exógena ter aumentado a produção de estradiol.

Thesis (M.S.)--Southern Illinois University Carbondale, 2005.<br>"Department of Medical Microbiology, Immunology, and Cell Biology." Includes bibliographical references (leaves 72-78). Also available online.

Made available in DSpace on 2014-08-20T13:32:47Z (GMT). No. of bitstreams: 1 dissertacao_lucas_teixeira_hax.pdf: 388762 bytes, checksum: c93c16af033ccd2aa4ff52ec81723de9 (MD5) Previous issue date: 2013-02-27<br>The genes of the somatotropic axis, which act regulating the metabolism and physiology of the mammals, present polymorphism associated to some characteristics of economical interest, such as reproductive performance and milk production. Such factors may be influenced by the mutation on only one nucleotide in the base sequence of the gene of the growth hormone receptor (GHR), which may alter the density of GHR on the hepatic tissue. Changes in the coupling of the growth hormone (GH) in the hepatic tissue alter the serum concentration of the insulin-like growth factor 1 (IGF-I), as IGF-I is produced mainly by the liver when it is stimulated by the growth hormone. Different studies have evaluated the effect of polymorphisms in the gene responsible for encoding IGF-I on the reproductive performance and milk production of high production dairy cows. Among other functions, the IGF-I mediates the effects of gonadotropins on the follicular cells, stimulating the growth and differentiation of theca and granulosa follicular cells, playing also a significant role on the final growth and maturation of the dominant follicle. Furthermore, high serum IGF-I concentrations are associated with a earlier return to cyclicity post partum in high yield dairy cows. Thus, the objective of this study was to evaluated the relevance of the mutations in GHR and IGF-I on the calving conception interval, number of inseminations per pregnancy and milk production in Holstein cows. One hundred and fifty five Holstein cows, submitted to a semi extensive management system, subjected to fixed-time artificial insemination (TAI) that got pregnant up to 250 days in milk in 2011, were selected. Among the animals tested, 29% presented GHR AluI (+ / +), 57.5% AluI (+ / -) and 13.5% AluI (- / -) genotype. 34.9% presented IGF-I SnaBI (+ / +), 45.8% SnaBI (+ / -) and 19.3% SnaBI (- / -) genotype. No association was observed between GHR AluI and IGF-I SnaBI genotypes and calving conception interval, number of inseminations per pregnancy and milk yield (P> 0.05). Likewise, there was no association between the interaction of GHR AluI and IGF-I SnaBI genotypes and calving conception interval, number of inseminations per pregnancy and milk yield (P> 0.05). Finally, further studies are necessary to better understand the relevance of GHR AluI and IGF-I SnaBI genotypes to the calving conception interval number of inseminations per pregnancy and milk production in Holstein cows.<br>Os genes do eixo somatotrópico, que atuam na regulação do metabolismo e fisiologia dos mamíferos, apresentam polimorfismos associados a algumas características de interesse econômico, como desempenho reprodutivo e produção de leite. Tais fatores podem ser influenciados por mutações de apenas um nucleotídeo na sequência de bases do gene do receptor do hormônio do crescimento (GHR), que podem alterar a expressão do GHR no tecido hepático. Mudanças no acoplamento do hormônio do crescimento (GH) no tecido hepático alteram a concentração sérica de fator de crescimento semelhante à insulina tipo1 (IGF-I), visto que o IGF-I tem sua produção endócrina principalmente no fígado mediante estimulação do hormônio do crescimento. Diversos trabalhos têm estudado o efeito de polimorfismos no gene que codifica para IGF-I no desempenho reprodutivo e produção de leite de vacas leiteiras de alta produção. Entre outras funções, o IGF-I atua como mediador dos efeitos das gonadotrofinas nas células foliculares, estimulando o crescimento e diferenciação das células da teca e da granulosa foliculares, apresentando também um importante papel no crescimento final e na maturação do folículo dominante. As altas concentrações sanguíneas de IGF-I estão também associadas a um retorno à ciclicidade mais precoce de vacas leiteiras pós-parto de alta produção. Dessa forma, o objetivo deste estudo foi avaliar a importância de mutações no GHR e IGF-I no desempenho zootécnico, IPC, número de inseminações por prenhez e produção de leite em vacas da raça Holandês. Foram avaliadas 155 vacas da raça Holandês em sistema semi extensivo submetidas à inseminação artificial em tempo fixo (IATF) e que conceberam até 250 dias em lactação no ano de 2011. Entre os animais analisados, 29% apresentaram o genótipo GHR AluI, (+/+), 57,5% AluI (+/-) e 13,5% AluI (-/-). Já para o IGF-I SnaBI 34,9% apresentaram o genótipo IGF-I SnaBI (+/+), 45,8% SnaBI (+/-) e 19,3% SnaBI (-/-). Não foi observada associação entre os genótipos GHR AluI e IGF-I SnaBI e o intervalo parto-concepção, número de inseminações por prenhez e produção de leite (P>0,05). Da mesma forma, não houve associação entre a interação dos genótipos de GHR AluI e IGF-I SnaBI e o intervalo parto-concepção, número de inseminações por prenhez e produção de leite (P>0,05). Finalmente, novos estudos avaliando uma maior população de animais são necessários para elucidar a importância dos genótipos de GHR AluI e IGF-I SnaBI no intervalo parto-concepção, número de inseminações por prenhez e produção de leite.

Este documento encontra-se dividido em três capítulos que correspondem aos estágios curriculares inseridos no plano pedagógico do Mestrado Integrado em Ciências Farmacêuticas. O primeiro capítulo diz respeito ao estágio em Farmácia Hospitalar, o qual proporcionou a consolidação de conhecimentos e uma visão integrada da importância e papel do serviço farmacêutico na área. Os temas abordados incidiram sobre: organização e gestão, distribuição, farmacotecnia, informação e documentação, assim como outras actividades farmacêuticas. O segundo capítulo refere-se ao estágio em Farmácia Comunitária. Este permitiu não só a consolidação de conhecimentos como também o contacto com a realidade da actividade. Os temas abordados recaíram sobre: organização da farmácia, informação e documentação, logística, dispensa de medicamentos, preparação de manipulados, contabilidade e gestão, aconselhamento farmacêutico e outros cuidados de saúde. O terceiro capítulo corresponde ao estágio em investigação. Este foi realizado no âmbito da genética humana com o objectivo de estudar o polimorfismo do exão 3 do receptor da hormona de crescimento numa população portuguesa. A prevalência dos três tipos de genótipos observada na população de 238 indivíduos voluntários da Região Centro foi de: 43,7%, 46,2% e 10,1% para os genótipos fl/fl, fl/d3 e d3/d3, respectivamente. Para a subpopulação de 139 voluntários com menos de 30 anos concluiu-se que, para um intervalo de confiança a 95%, não existem diferenças estatisticamente significativas entre as médias de estaturas dos diferentes grupos de genótipos. Também se concluiu que, para uma população de 20 doentes com deficiência de hormona de crescimento ou Síndrome de Turner, não existem diferenças estatisticamente significativas entre os grupos de genótipos analisados relativamente ao aumento do desvio padrão estatural após um ano de terapia com hormona de crescimento recombinante. Com vista à melhoria da saúde pública, o farmacêutico corre diariamente numa busca incessante pela qualidade, o que exige a constante actualização dos seus conhecimentos multidisciplinares.<br>This document is divided into three chapters which correspond to the curricular internship included in the pedagogical plan of the Master degree in Pharmaceutical Sciences. The first chapter concerns the internship in Hospital Pharmacy, which provided the consolidation of knowledge and an integrated view of the importance and role of the pharmaceutical service in the area. The topics focused on organization and management, distribution, pharmacotechnics, information and documentation as well as other pharmaceutical activities. The second chapter refers to the internship in Community Pharmacy. This allowed not only the consolidation of knowledge as well the contact with the reality of business. The topics fell on: organization of the pharmacy, information and documentation, logistics, dispensing medications, compounded drugs, accounting and management, counseling and other pharmaceutical care. The third chapter corresponds to the internship in scientific research. This was carried out in human genetics to study the polymorphism of the exon 3 of the growth hormone receptor in a portuguese population. The prevalence observed for the three types of genotypes in a population of 238 volunteers of the Central Region was: 43.7%, 46.2% and 10.1% for genotypes fl / fl, d3/d3 and fl/d3, respectively. For the subpopulation of 139 volunteers with less than 30 years it has been concluded that, for a confidence interval of 95%, there is no difference statistically significative between the average heights of the different genotype groups. The group of 20 patients with growth hormone deficiency and Turner's syndrome studied didn’t show differences statistically significative between the genotypes examined and the height standard deviation increase after a year of therapy with recombinant human growth hormone. In order to improve public health, the pharmacist runs daily in a relentless pursuit of quality, which requires the constant updating of their multidisciplinary knowledge.

Η αυξητική ορμόνη (GH), πολυλειτουργική ορμόνη που παράγεται από τα σωματοτρόπα κύτταρα του πρόσθιου λοβού της υπόφυσης, προάγει την μεταγεννητική ανάπτυξη σκελετικών και μαλακών ιστών. Επίσης, ασκεί ποικίλες άλλες βιολογικές δράσεις, όπως ρύθμιση του μεταβολισμού των υδατανθράκων, των πρωτεϊνών και του λίπους. Κατά συνέπεια, η ανεπάρκεια της εκτός από αναπτυξιακά μπορεί να προκαλέσει και σοβαρά μεταβολικά προβλήματα. Η GH δρα στους περιφερικούς ιστούς άμεσα αλλά και έμμεσα μέσω του ινσουλινόμορφου αυξητικού παράγοντα IGF-I. Μετά από πρόσδεση της GH στον υποδοχέα της (GHR), ο IGF-I παράγεται στο ήπαρ, όπου απελευθερώνεται στην γενική κυκλοφορία, αλλά παράγεται και τοπικά στους περιφερικούς ιστούς, όπου δρα με αυτοκρινή ή παρακρινή τρόπο. Η έκκριση της GH από την υπόφυση έχει παλμική μορφή και ρυθμίζεται κυρίως μέσω τριών υποφυσιοτρόπων παραγόντων: εκλυτική ορμόνη της GH (GHRH), σωματοστατίνη (SRIF) και γκρελίνη. Η απελευθέρωση της GHRH και της SRIH από τον υποθάλαμο επηρεάζεται και από μια ποικιλία άλλων νευροδιαβιβαστών, νευροορμονών και νευροπεπτιδίων. Έχει υπολογιστεί σε διάφορες μελέτες ότι κοντό ανάστημα συσχετιζόμενο με ανεπάρκεια της αυξητικής ορμόνης (GHD) παρατηρείται με συχνότητα 1 στις 4000 έως 1 στις 10000 γεννήσεις. Παρόλο που οι περισσότερες περιπτώσεις είναι σποραδικές και θεωρούνται αποτέλεσμα περιβαλλοντικών εγκεφαλικών προσβολών ή αναπτυξιακών ανωμαλιών, γενετική αιτιολογία προτείνεται περίπου στο 10% των GHD περιπτώσεων, λόγω του ότι έχει προσβληθεί ένας τουλάχιστον πρώτου βαθμού συγγενής. Η διάγνωση της GHD είναι μια πολύπλευρη διαδικασία που απαιτεί εκτενή κλινική εκτίμηση, αξιολόγηση σωματομετρικών παραμέτρων, βιοχημικές δοκιμασίες του GH-IGF άξονα, και ακτινολογική εκτίμηση. Η GHD μπορεί να παρουσιάζεται είτε ως μεμονωμένο πρόβλημα (IGHD) είτε σε συνδυασμό με πολλαπλές ορμονικές ανεπάρκειες (CPHD). Μοντέλα ζώων έχουν χρησιμοποιηθεί για μελέτη της φυσιολογικής λειτουργίας του υποθαλαμικού-GH άξονα και των πιθανών διαταραχών που οδηγούν σε IGHD/CPHD στους ανθρώπους. Σύμφωνα με τα κλινικά χαρακτηριστικά, τον τρόπο κληρονομικότητας και την ανταπόκριση στην εξωγενή θεραπεία, τέσσερις τύποι οικογενούς IGHD έχουν περιγραφεί στον άνθρωπο. Μεταλλαγές έχουν βρεθεί να συμβαίνουν στο GH γονίδιο (GH1) και στο γονίδιο του υποδοχέα της GHRH (GHRH-R). Πολυμορφισμοί στον υποκινητή του GH1 γονιδίου μειώνουν επίσης την έκφραση του. Πρόσφατα, μεταλλαγές στο γονίδιο του υποδοχέα της γκρελίνης (GHS-R) συσχετίστηκαν με IGHD. Μεταλλαγές σε διακριτά γονίδια μεταγραφικών παραγόντων, που είναι βασικά για την ανάπτυξη και διαφοροποίηση των κυττάρων του πρόσθιου λοβού της υπόφυσης, όπως Pit1/POU1F1, PROP1, HESX1, LHX3, LHX4, έχουν αναγνωρισθεί μέχρι σήμερα σε ανθρώπους με CPHD. Καθώς μεγάλο ποσοστό οικογενών περιπτώσεων IGHD/CPHD δεν οφείλεται σε μεταλλαγές σε κάποιο από τα ήδη γνωστά γονίδια, φαίνεται να εμπλέκονται μεταλλαγές σε επιπρόσθετα υποψήφια γονίδια. Περαιτέρω γενετικές μελέτες μπορούν να συμβάλλουν σε καλύτερη κατανόηση της GHD, σε πρώιμη διάγνωση και βελτίωση της θεραπευτικής αγωγής στα άτομα με GHD.<br>Growth hormone (GH), a multifunctional hormone which is synthesized in the somatotrope cells of the anterior pituitary gland, promotes postnatal development of skeletal and soft tissues. In addition, GH exerts multiple biological actions, such as regulating the metabolism of carbohydrates, proteins and fat. Consequently, GH deficiency (GHD) apart from causing developmental disorders can also have a deleterious effect on the body’s metabolism. GH acts on peripheral tissues both directly and indirectly, through the mediation of insulin-like growth factor-1 (IGF-1). Upon binding of GH to its receptor (GHR), IGF-1 is produced both in the liver, from where it is released into the general circulation, and locally in the peripheral tissues, such as bone, cartilage, and muscle, where it acts in an autocrine or paracrine fashion. GH is secreted from the pituitary gland in a pulsatile fashion. Major regulatory factors include three hypophysiotropic factors: GH releasing hormone (GHRH), somatostatin (SRIF), and ghrelin. Moreover, GH secretion can be affected by a variety of other neurotransmitters, neurohormones and neuropeptides. The diagnosis of GHD demands detailed clinical, auxological, radiological and biochemical evaluation of the GH-IGF axis. GHD may occur as isolated GHD (IGHD) or in combination with other pituitary hormone deficiencies (Combined Pituitary Hormone Deficiency, CPHD). The physiological actions of the hypothalamic-GH axis and the possible disorders leading to IGHD/CPHD in humans have been extensively studied in animal models. Short stature associated with GHD has been estimated to occur in about 1/4000-1/10000 in various studies. Whereas most cases are sporadic and believed to result from environmental cerebral insults or developmental anomalies, approximately 10% of the affected individuals have a first-degree relative with the same disorder, suggesting a hereditary trend and genetic factors affecting the disorder. Four types of familial IGHD have been described in humans according to clinical characteristics, the mode of inheritance and the response to exogenous therapy. Mutations reducing gene expression have been described in the GH1 gene and in the GHRH receptor (GHRH-R) gene. Polymorphisms found in the promoter of the GH1 gene can also reduce its expression. Recently, mutations in the ghrelin receptor (GHS-R) gene were associated with IGHD. Mutations in discrete genes of transcriptional factors necessary for the development and differentiation of anterior pituitary cells, such as Pit1/POU1F1, PROP1, HESX1, LHX3, LHX4 have been recognized in individuals with CPHD. Considering that a large proportion of familial cases of IGHD/CPHD are not caused by mutations in any of the known genes, mutations in additional candidate genes may be involved. Further genetic studies may contribute to a better understanding of GHD, earlier diagnosis and better therapeutic approaches for this disorder.

Dans les cellules somatotropes, la liaison du facteur de libération de l’hormone de croissance (GHRH) à son récepteur (GHRH-R) stimule la synthèse et la sécrétion de l’hormone de croissance (GH) ainsi que la prolifération cellulaire. Chez les mammifères, le vieillissement est caractérisé par une diminution de la sécrétion de GH, liée à une perte de sensibilité des somatotropes au GHRH. Chez le rat âgé, des modifications de niveaux d'ARNm du GHRH-R et une diminution d'affinité et de capacité de liaison du GHRH sont rapportés. Au cours du vieillissement, une augmentation des niveaux de glucose et d’acides gras libres sérique suggère qu’une gluco- ou lipotoxicité puisse contribuer au dysfonctionnement de la fonction somatotrope. À ce jour, la restriction calorique modérée de longue durée (RCMLD) constitue l’intervention la plus efficace pour prévenir ou retarder les détériorations liées à l’âge. Des études ont montré des effets bénéfiques de la RCMLD sur l’axe somatotrope au cours du vieillissement via un maintien des paramètres de liaison du GHRH-R. Compte tenu de l’importance de cet axe, la compréhension des mécanismes menant à la somatopause ainsi que ceux associés aux effets bénéfiques de la RCMLD s’avère importante. Les objectifs principaux de la présente thèse étaient : 1) de déterminer les effets de la RCMLD chez le rat, sur le GHRH-R hypophysaire et la sensibilité des somatotropes au GHRH, 2) d’identifier les mécanismes associés à la somatopause et aux effets bénéfiques de la RCMLD, et 3) de préciser les effets d’une gluco-ou lipotoxicité sur l’axe somatotrope de rats et leur implication dans la somatopause. Des rats de 8 mois ont été soumis à une restriction calorique de 40% jusqu’à l’âge de 18-20 mois et ont été comparés à des rats jeunes et âgés nourris ad libitum. Cette étude a permis de mettre en évidence des effets bénéfiques de la RCMLD sur la régulation et la fonctionnalité du GHRH-R et de proposer que le glucose et les acides gras libres (AGL) circulants soient impliqués dans le vieillissement de la somatotrope. Une étude de micro-puce à ADN à permis d’identifier des gènes associés à des mécanismes de protection et de réparation des dommages cellulaires mis en place dans l’hypophyse antérieure au cours du vieillissement et par la RCMLD. Finalement, les effets d’un stress gluco- ou lipotoxique sur la fonction somatotrope ont été étudiés chez des rats de 2 et 6 mois, infusés 72 h avec une solution de glucose ou d’Intralipides, mimant les niveaux circulants de glucose et d’AGL retrouvés chez le rat âgé. Les résultats obtenus montrent que la glucotoxicité affecte la régulation de certains gènes de la somatotrope, dont le GHRH-R, et suggèrent que la capacité de réponse à ce type de stress est altérée. Les mécanismes par lesquels la glucotoxicité exerce ces effets pourraient inclure la génération de stress oxydant. L’ensemble de ces résultats proposent de nouvelles pistes mécanistiques qui pourraient contribuer au retardement de la somatopause et, ultimement, à l’élaboration de nouvelles stratégies d’intervention nutritionnelles ou pharmacologiques ciblant les mêmes voies que la RCMLD, avec une efficacité similaire ou supérieure.<br>In somatotroph cells, growth hormone-releasing hormone (GHRH) binding to its receptor (GHRH-R) stimulates growth hormone (GH) secretion and cell proliferation. In mammals, aging is characterized by a decrease of GH, associated with a decline of GHRH somatotroph sensitivity. In the aged rat, changes in GHRH-R mRNA levels and decrease of GHRH affinity and capacity were reported. In the course of aging, significant increase of glucose and free fatty acid (FFA) serum levels are observed, suggesting that gluco- or lipotoxicity could contribute to somatotroph dysfunction. Up to now, long-term moderate caloric restriction (LTMCR) has been the most efficient intervention to prevent or delay age-related deteriorations. Studies have shown beneficial effects of LTMCR on somatotroph axis during aging, through the maintenance of GHRH-R binding parameters. Knowing the importance of this axis, an understanding of the mechanisms associated with the effects of somatopause and benefits of LTMCR is important. Therefore, the main objectives of this thesis were: 1) to determine the effects of LTMCR on rat pituitary GHRH-R and somatotroph sensitivity to GHRH, 2) to identify the mechanisms associated to somatopause and the beneficial effects of LTMCR and 3) to specify the effect of gluco- or lipotoxicity on the rat somatotroph axis and their implications in somatopause. Eight-month-old rats were submitted to a 40% LTMCR until the age of 18 to 20-months and where compared to young and old rats fed ad libitum (AL). This study highlighted beneficial effects of LTMCR on GHRH-R regulation and functionality and suggested that high circulating levels of glucose and FFA could be involved in somatotroph aging. A microarray study was also performed, allowing the identification of genes associated to cellular protection and damage repair mechanisms regulated by aging and LTMCR in the anterior pituitary. Finally, effects of a gluco- or lipotoxic stress on the somatotroph function was assessed in 2- and 6-month-old rats submitted to a 72-h glucose and/or Intralipid infusion, to mimic the levels of glucose and FFA found in aged rats. The results showed that glucotoxicity affects the regulation of specific genes in the somatotroph, such as the GHRH-R gene, and suggest that the response capacity against this type of stress is altered with age very early on. Mechanisms by which glucotoxicity exerts these effects might include oxidative stress production. Altogether, these results proposed novel mechanisms that could contribute to delay somatopause and, ultimately, to the development of new nutritional or pharmacologic interventions targeting the same pathways as LTMCR, with a similar or greater efficiency.

Les azapeptides sont des mimes peptidiques où le carbone alpha d’un ou de plusieurs acides aminés est remplacé par un atome d’azote. Cette modification tend à stabiliser une conformation en repliement beta en raison de la répulsion électronique entre les paires d’électrons libres des atomes d’azote adjacents et de la géométrie plane de l’urée. De plus, le résidu semicarbazide a une meilleure résistance face aux protéases en plus d’être chimiquement plus stable qu’une liaison amide. Bien que les propriétés des azapeptides en fassent des mimes peptidiques intéressants, leurs méthodes de synthèses font appel à la synthèse laborieuse d’hydrazines substituées en solution. Le peptide sécréteur d’hormone de croissance 6 (GHRP-6, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) est un hexapeptide synthétique qui possède une affinité pour deux récepteurs distincts: les récepteurs GHS-R1a et CD36. Les travaux effectués au cours de mon doctorat qui seront détaillés dans cet ouvrage visent à atteindre deux objectifs: (1) le développement d’analogues du peptide GHRP-6 sélectif à un seul récepteur et (2) la mise au point d’une nouvelle méthodologie pour la synthèse combinatoire d’azapeptides. En réponse au premier objectif, la synthèse parallèle de 49 analogues aza-GHRP-6 a été effectuée et certains candidats sélectifs au récepteur CD36 ont été identifiés. L’étude de leurs propriétés anti-angiogéniques, effectuée par nos collaborateurs, a également permis d’identifier des candidats intéressants pour le traitement potentiel de la dégénérescence maculaire liée à l’âge. Une nouvelle approche pour la synthèse combinatoire d’azapeptides, faisant appel à l’alkylation et la déprotection chimiosélective d’une sous-unité semicarbazone ancrée sur support solide, a ensuite été développée. La portée de cette méthodologie a été augmentée par la découverte de conditions permettant l’arylation régiosélective de cette sous-unité semicarbazone, donnant accès à treize nouveaux dérivés aza-GHRP-6 possédant des résidus aza-arylglycines aux positions D-Trp2 et Trp4. L’élaboration de conditions propices à l’alkylation et la déprotection chimiosélective de la semicarbazone a donné accès à une variété de chaînes latérales sur l’acide aminé « aza » préalablement inaccessibles. Nous avons, entre autres, démontré qu’une chaîne latérale propargyl pouvait être incorporée sur l’acide aminé « aza ». Tenant compte de la réactivité des alcynes, nous avons ensuite élaboré des conditions réactionnelles permettant la formation in situ d’azotures aromatiques, suivie d’une réaction de cycloaddition 1,3-dipolaire sur support solide, dans le but d’obtenir des mimes de tryptophane. Sept analogues du GHRP-6 ont été synthétisés et testés pour affinité au récepteur CD36 par nos collaborateurs. De plus, nous avons effectué une réaction de couplage en solution entre un dipeptide possédant un résidu aza-propargylglycine, du paraformaldehyde et une variété d’amines secondaires (couplage A3) afin d’accéder à des mimes rigides d’aza-lysine. Ces sous-unités ont ensuite été incorporées sur support solide afin de générer sept nouveaux azapeptides avec des dérivés aza-lysine à la position Trp4 du GHRP-6. Enfin, une réaction de cyclisation 5-exo-dig a été développée pour la synthèse de N-amino imidazolin-2-ones en tant que nouveaux mimes peptidiques. Leur fonctionnalisation par une série de groupements benzyliques à la position 4 de l’hétérocycle a été rendue possible grâce à un couplage Sonogashira précédant la réaction de cyclisation. Les propriétés conformationnelles de cette nouvelle famille de composés ont été étudiées par cristallographie aux rayons X et spectroscopie RMN d’un tétrapeptide modèle. L’activité biologique de deux mimes peptidiques, possédant un résidu N-amino-4-méthyl- et 4-benzyl-imidazolin-2-one à la position Trp4 du GHRP-6, a aussi été examinée. L’ensemble de ces travaux devrait contribuer à l’avancement des connaissances au niveau des facteurs structurels et conformationnels requis pour le développement d’azapeptides en tant que ligands du récepteur CD36. De plus, les résultats obtenus devraient encourager davantage l’utilisation d’azapeptides comme peptidomimétiques grâce à leur nouvelle facilité de synthèse et la diversité grandissante au niveau de la chaîne latérale des acides aminés « aza ».<br>Azapeptides are peptide mimics in which the CH alpha in one or more amino acids has been replaced with a nitirogen atom. Such a modification tends to induce beta turn conformations in peptides, because of the consequences of lone–pair lone–pair repulsion between the two adjacent nitrogens and the planar geometry of the urea in the semicarbazide moiety. Furthermore, the semicarbazide increases protease resistance and is chemically more stable than its amide counterpart. Despite the potential advantages of using azapeptides mimics, their synthesis has been hampered by the solution-phase construction of substituted hydrazines prior to their incorporation into peptide sequences. Growth Hormone Releasing Peptide 6 sequence (GHRP-6, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic hexapeptide that binds to two distinct receptor: the Growth Hormone Secretatgogue Receptor 1a (GHS-R1a) and the Cluster of Differentiation 36 (CD36) receptor. The body of my Ph.D thesis has been generally targeted towards two objectives: (a) the development of azapeptide analogs of GHRP-6 with enhanced receptor selectivity and (b) the elaboration of a new synthetic approach for combinatorial submonomer azapeptide synthesis. In response to the first objective, 49 aza-GHRP-6 derivatives were synthesized and evaluated for receptor binding and biological activity. From this library, certain candidates were identified which exhibited decreased affinity for the GHS-R1a receptor with maintained affinity for the CD36 receptor. Furthermore, in studying their anti-angiogenic properties, our collaborators have identified aza-GHRP-6 analogs, which caused a marked decrease in microvascular sprouting in choroid explants, as well as another displaying potential to increase angiogenesis. A new approach for the combinatorial synthesis of azapeptides was developed to better conduct SAR studies using azapeptides. This method features the chemoselective alkylation and deprotection of a resin-bound semicarbazone building block. The scope of the methodology was further expanded by the development of reaction conditions for the chemoselective N-arylation of this semicarbazone residue, yielding 13 aza-GHRP-6 derivatives with aza-arylglycines residues at the D-Trp2 and Trp4 positions. The elaboration of a methodology based on the chemoselective alkylation and deprotection of a semicarbazone has allowed for greater aza-amino acid side chain diversity, enabling for example, the efficient incorporation of aza-propargylglycine residues into peptide sequences. Considering the reactivity of alkynes, we developed reaction conditions for in situ formation of aromatic azides, followed by a 1,3-dipolar cycloaddition reaction on solid support to yield aza-1-aryl,2,3-triazole-3-alanine residues as tryptophan mimics. Seven aza-GHRP-6 analogs were synthesized and subsequently tested for binding to the CD36 receptor by our collaborators. Moreover, the coupling reaction between an aza-propargylglycine-containing dipeptide building block, paraformaldehyde and a variety of secondary amines (A3 coupling) was accomplished in solution to provide access to rigid aza-lysine mimics. These aza-dipeptides were subsequently incorporated at the Trp4 position of seven new aza-GHRP-6 analogues using a solid-phase protocol, and the resulting azaLys mimics were tested for binding towards the CD36 receptor. Finally, conditions for a 5-exo-dig cyclization of an aza-propargylglycine residue were developed to give N-amino imidazolin-2-ones as turn-inducing peptide mimics. Their modification at the 4 position was achieved using a Sonogashira coupling protocol prior to the cyclization step. The conformational properties of these new heterocyclic motifs were assessed by X-ray crystallography and NMR spectroscopy on a tetrapeptide model system. The incorporation of N-amino-4-methyl- and 4-benzyl-imidazolin-2-ones at the Trp4 position of GHRP-6 was further accomplished and the biological evaluation of the peptidomimetics was examined. Taken together, these results should lead to a better understanding of the structural and conformational factors responsible for binding and biological activity of azapeptide ligands of the CD36 receptor. Furthermore, the submonomer approach for azapeptide synthesis developed should promote the use of azapeptides as peptide mimics, given its accessibility and the increased aza-amino acid side-chain diversity available.

Les prodrogues sont des dérivés biologiquement inactifs d’un principe actif qui, après administration à un organisme, subissent une transformation chimique ou enzymatique pour libérer le principe actif au site d’action. Elles améliorent les propriétés physicochimiques du principe actif pour permettre un meilleur transport à travers les barrières biologiques et pour augmenter l’activité in vivo. Elles sont utilisées pour améliorer la formulation et l’administration, accroître la perméabilité et l’absorption, modifier le profil de distribution et éviter le métabolisme et la toxicité. Cette approche est très utile pour améliorer l'administration de principes actifs. Il existe deux types de prodrogues : les prodrogues liées à un transporteur et les bioprécurseurs. Dans le premier cas, la molécule active est liée par une liaison covalente à un groupement temporaire, ce qui fournit une nouvelle molécule, qui est inactive. Le groupement temporaire libéré ne doit pas avoir, par lui-même, d'action pharmacologique ni de toxicité. Dans le second cas, le principe actif est transformé métaboliquement ou chimiquement par réaction d’hydratation, d’oxydation ou de réduction. Les azapeptides sont des mimes peptidiques dans lesquels un ou plusieurs carbones de la chaîne peptidique sont remplacés par des atomes d’azote. Ce remplacement augmente la rigidité de la chaîne peptidique et favorise le repliement de type β. Le repliement β des azapeptides est associé à plusieurs propriétés thérapeutiques. Certains azapeptides ont montré une meilleure activité, une meilleure sélectivité et une plus grande stabilité comparativement aux peptides parents ce qui prolonge leur durée d'action et les rend plus résistants aux dégradations métaboliques. Ce mémoire s’intéresse particulièrement à l’azapeptide : [aza(p-MeO)F⁴]-GHRP-6. Celui-ci est un analogue du peptide sécréteur d’hormone de croissance 6 (GHRP-6, H-His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂), qui possède une affinité pour deux récepteurs distincts : les récepteurs de growth hormone secretagogue receptor 1a (GHS-R1a) et le récepteur cluster of differentiation 36 (CD36). L’[aza(p-MeO)F⁴]-GHRP-6 démontre une sélectivité envers le récepteur CD36 offrant des possibilités de traitement de maladies telles que l’athérosclérose et la dégénérescence maculaire liée à l’âge (DMLA). De plus, le récepteur CD36 peut interagir avec un corécepteur toll-like receptor 2 (TLR2), et l’[aza(p-MeO)F⁴]-GHRP-6 peut réduire des réponses immunitaires innées. La stratégie des prodrogues a été utilisée dans ce mémoire pour augmenter la durée d’action de l’azapeptide [aza(p-MeO)F⁴]-GHRP-6. Plus précisément, cinq analogues des prodrogues α-acyloxyéthylcarbamates de l’aza(p-MeO)F⁴-GHRP-6 ont été synthétisées. Ce mémoire présente la première synthèse de prodrogues α-acyloxyéthylcarbamates à caractère PEG de l’[aza(p-MeO)F⁴]-GHRP-6.<br>A prodrug is a biologically inactive derivative of a drug which after administration undergoes chemical or enzymatic modification to release the active drug at targeted sites of activity. Prodrugs improve physicochemical properties to enable better transport through biological barriers and enhance activity. They are used to improve formulation and administration, to enhance permeability and absorption, to modify distribution profiles and to avoid metabolism and toxicity. The prodrug approach is useful for improving drug delivery. Prodrugs are classified into two types: carrier-linked prodrugs and bio-precursors. In the first case, the parent drug is linked by a covalent bond to an inert carrier or transport moiety. The carrier should not be active or toxic. The active drug is released by a chemical or enzymatic cleavage in vivo. In the second case, the parent drug is converted metabolically or chemically by hydration, oxidation or reduction reactions. Azapeptides employ a semicarbazide as an amino amide surrogate in a peptide analog in which the backbone α-CH is replaced by nitrogen. Through electronic interactions, the semicarbazide favors backbone β-turn geometry due to a combination of urea planarity and hydrazine nitrogen lone pair – lone pair repulsion. Azapeptides have proven therapeutic utility. Some of them exhibit better selectivity, activity and stability than the parent peptides with increased duration of action and improved metabolic stability. Growth hormone releasing peptide-6 (GHRP-6, H-His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂) is a synthetic peptide possessing an affinity for two different receptors: growth hormone secretagogue receptor 1a (GHS-R1a) and cluster of differentiation receptor 36 (CD36). The GHRP-6 azapeptide analogue, [aza(p-MeO)F⁴]-GHRP-6, has exhibited good affinity for CD36 and reduced nitric oxide overproduction in macrophage cells stimulated with the TLR-2 agonist R-FSL-1. Azapeptide ligands of CD36, such as [aza(p-MeO)F⁴]-GHRP-6, offers potential as prototypes for developing treatments of diseases such as atherosclerosis and age-related macular degeneration. A prodrug strategy has been pursued to improve the pharmacokinetic properties, such as duration of action, of [aza(p-MeO)F⁴]-GHRP-6. The first examples of α-acyloxyethyl carbamate peptides have been prepared. Five α-acyloxyethyl carbamate analogues of [aza(p-MeO)F⁴]-GHRP-6 have been synthesized by routes featuring acylation of the resin-bound peptide using different activated α-acyloxyethyl carbonates prior to resin cleavage and side chain deprotection. The evaluation of the activity of the pharmacokinetic properties of the [aza(p-MeO)F⁴]-GHRP-6 prodrugs is currently in progress and will be reported in due time.